Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial
Sign Up to like & getrecommendations! Published in 2022 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2021.103811
Abstract: Background We report on the safety and immunogenicity of V591, a measles vector-based SARS-CoV-2 vaccine candidate. Methods In this multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial, healthy adults with no history of COVID-19 disease were… read more here.
Keywords: safety immunogenicity; sars cov; v591; placebo ... See more keywords